Earnings Call · Q2 FY2024·2024-08-13

Q2 24EPS +18.67%·Rev n/aQ1 24EPS +9.72%·Rev n/aQ4 23EPS +25.84%·Rev n/aQ3 23EPS +30.11%·Rev n/a⚠ consensus missing

LISATA THERAPEUTICS, INC. LSTA

John Menditto — Head of Investor Relations

David Mazzo — President and Chief Executive Officer

James Nisco — Chief Financial Officer

Kristen Buck — Executive Vice President

+0.4%1d on move date−1.3% vs SPY3d−1.3%5d+1.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LSTA calls or request research access.

More LSTA calls Browse calls Request research access